Your browser doesn't support javascript.
loading
New targets for NAFLD.
Parlati, Lucia; Régnier, Marion; Guillou, Hervé; Postic, Catherine.
Afiliação
  • Parlati L; Université de Paris, Institut Cochin, CNRS, INSERM, F- 75014 Paris, France.
  • Régnier M; Hôpital Cochin, 24, rue du Faubourg Saint Jacques, 75014 Paris, France.
  • Guillou H; UCLouvain, Université catholique de Louvain, Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Brussels, Belgium.
  • Postic C; Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France.
JHEP Rep ; 3(6): 100346, 2021 Dec.
Article em En | MEDLINE | ID: mdl-34667947
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD. In this review, we will provide an update on the known molecular pathways involved in the pathophysiology of NAFLD and on ongoing studies of new therapeutic targets.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: JHEP Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: JHEP Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França País de publicação: Holanda